Carla Leibowitz is Chief Business Officer at Verge Genomics, where she leads growth, partnerships and strategy for the company's AI-driven drug discovery platform. She's spent her career bringing AI in healthcare from concept to the clinic. She was Chief Business Officer at Paige, where she helped bring the first AI product in pathology through FDA clearance and CE mark. Before that, she led Corporate Development and Strategy at Arterys, the first company to get FDA clearance for AI in radiology. At Flatiron Health, she served as VP of Business and Corporate Development, leading growth initiatives and strategic partnerships, including building the analytics business. Across these roles, Carla has led and built the commercial and partnership strategies that brought multiple first-in-class AI products to market. She has an MBA from Stanford GSB and engineering degrees from MIT and Stanford.